Trial Updates

Highlights from AD/PD: Donanemab & iADRS 3:45
Highlights from AD/PD: Donanemab & iADRS
Suzanne Hendrix • 17 Mar 2021
Gamma frequency neuromodulation in AD: results from the Overture study 3:39
Gamma frequency neuromodulation in AD: results from the Overture study
Suzanne Hendrix • 17 Mar 2021
A post-hoc analysis of LipidiDiet: ADCOMS, GST & BHA 4:23
A post-hoc analysis of LipidiDiet: ADCOMS, GST & BHA
Suzanne Hendrix • 17 Mar 2021
Online registries allow rapid recruitment of diverse populations for AD trials 1:46
Online registries allow rapid recruitment of diverse populations for AD trials
Stephen Salloway • 10 Mar 2021
PASADENA trial: prasinezumab in early Parkinson’s disease 1:24
PASADENA trial: prasinezumab in early Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
Learnings from the PASADENA trial in Parkinson’s disease 1:49
Learnings from the PASADENA trial in Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
Donanemab in early-stage AD: a highlight from AD/PD 2:16
Donanemab in early-stage AD: a highlight from AD/PD
Sangram Sisodia • 16 Mar 2021
The AD pipeline and role of amyloid-beta 5:59
The AD pipeline and role of amyloid-beta
Jeffrey Cummings • 15 Mar 2021
Highlights from AD/PD: novel therapies, technologies and analytics 4:18
Highlights from AD/PD: novel therapies, technologies and analytics
Jeffrey Cummings • 15 Mar 2021
Clinical trial of RGn530 photobiomodulation device on Alzheimer’s disease 6:07
Clinical trial of RGn530 photobiomodulation device on Alzheimer’s disease
Jacques Touchon • 10 Mar 2021
MCLENA-1: lenalidomide in mild cognitive impairment due to Alzheimer’s disease 2:26
MCLENA-1: lenalidomide in mild cognitive impairment due to Alzheimer’s disease
Marwan Sabbagh • 8 Mar 2021
ALZ-801: oral anti-amyloid agent for Alzheimer’s disease 1:38
ALZ-801: oral anti-amyloid agent for Alzheimer’s disease
Marwan Sabbagh • 8 Mar 2021
CNM-Au8 gold nanocatalysts to slow disease progression in ALS 3:11
CNM-Au8 gold nanocatalysts to slow disease progression in ALS
Robert Glanzman • 1 Mar 2021
Challenges in treating aging: public acceptance and biomarkers 3:13
Challenges in treating aging: public acceptance and biomarkers
Tal Iram • 4 Mar 2021
Is long-term teriflunomide treatment safe in MS? 2:13
Is long-term teriflunomide treatment safe in MS?
Mark Freedman • 3 Mar 2021
The perpetual multi-center multi-regimen Healy-ALS Platform trial 0:46
The perpetual multi-center multi-regimen Healy-ALS Platform trial
Robert Glanzman • 1 Mar 2021
The content of VJNeurology is intended for healthcare professionals